<?xml version="1.0" encoding="UTF-8"?>
<p id="Par27">While the clinical impact of Early Access to ART for All (EAAA) is evident, critical implementation questions remain. Recently, results from the Treatment as Prevention (TasP) Trial in rural KwaZulu-Natal in South Africa did not demonstrate a difference in HIV incidence between communities randomized to either immediate offer of ART for all HIV-positive individuals compared to the standard of care [
 <xref ref-type="bibr" rid="CR9">9</xref>]. The study results demonstrated not only the need for high rates of linkages to care following diagnosis, but also the importance of understanding how to best deliver early ART in southern Africa. As the latest WHO guidelines are recommending EAAA [
 <xref ref-type="bibr" rid="CR10">10</xref>] and countries in sub-Saharan Africa start to follow this recommendation [
 <xref ref-type="bibr" rid="CR11">11</xref>], the critical question is no longer whether EAAA should be implemented, but rather how to implement it in resource-limited settings where the epidemic is most prevalent.
</p>
